Company
Ventana
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
28
510(k), De Novo and PMA
Device trials
0
As lead sponsor, any status
Adverse event reports
39
Received Nov 1, 2025 to Nov 20, 2026
Recall records
56
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
From SEC filings.
We found no SEC financing filings under the name Ventana, so its financing is unknown here. That is common for companies based outside the US, for subsidiaries of larger companies, and for companies funded by founders, grants or customers. A company that changed its name can also be missed.
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
No 5%+ shareholder filings or SBIR grants found under the name Ventana.
Latest FDA decisions
The 8 newest of 28 since 2015.
- VENTANA HER2 Dual ISH DNA Probe CocktailPMA supplement
P190031-S016 · Decided Aug 25, 2026 · 153 days after receipt · Panel Track
Device type: Chromogenic In Situ Hybridization, Nucleic Acid Amplification, Her2/Neu Gene, Breast Cancer (NYQ) · Laboratory Medicine & Pathology
P990081-S060 · Decided Aug 25, 2026 · 153 days after receipt · Panel Track
Device type: SYSTEM, TEST, HER-2/NEU, IHC (MVC) · Laboratory Medicine & Pathology
P250031 · Decided Jun 12, 2026 · 298 days after receipt
Device type: Immunohistochemistry Assay, Antibody (SHF) · Laboratory Medicine & Pathology
25 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
No device trials list this company as lead sponsor.
Reports received
39
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
32
82% of reports
Injury reports
7
18% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 1 | 0 | 0 | 0 |
| Jan 24 | 2 | 0 | 0 | 0 |
| Feb 24 | 1 | 1 | 0 | 0 |
| Mar 24 | 1 | 0 | 0 | 0 |
| Apr 24 | 1 | 0 | 0 | 0 |
| May 24 | 0 | 0 | 0 | 0 |
| Jun 24 | 2 | 1 | 0 | 0 |
| Jul 24 | 1 | 0 | 0 | 0 |
| Aug 24 | 0 | 0 | 0 | 0 |
| Sep 24 | 0 | 0 | 0 | 0 |
| Oct 24 | 0 | 0 | 0 | 0 |
| Nov 24 | 1 | 0 | 0 | 0 |
| Dec 24 | 0 | 1 | 0 | 0 |
| Jan 25 | 0 | 0 | 0 | 0 |
| Feb 25 | 1 | 0 | 0 | 0 |
| Mar 25 | 0 | 1 | 0 | 0 |
| Apr 25 | 4 | 0 | 0 | 0 |
| May 25 | 0 | 0 | 0 | 0 |
| Jun 25 | 3 | 0 | 0 | 0 |
| Jul 25 | 0 | 0 | 0 | 0 |
| Aug 25 | 1 | 1 | 0 | 0 |
| Sep 25 | 0 | 0 | 0 | 0 |
| Oct 25 | 0 | 0 | 0 | 0 |
| Nov 25 | 0 | 0 | 0 | 0 |
| Dec 25 | 1 | 3 | 0 | 0 |
| Jan 26 | 4 | 1 | 0 | 0 |
| Feb 26 | 3 | 0 | 0 | 0 |
| Mar 26 | 2 | 0 | 0 | 0 |
| Apr 26 | 6 | 1 | 0 | 0 |
| May 26 | 4 | 0 | 0 | 0 |
| Jun 26 | 2 | 0 | 0 | 0 |
| Jul 26 | 2 | 0 | 0 | 0 |
| Aug 26 | 1 | 1 | 0 | 0 |
| Sep 26 | 3 | 0 | 0 | 0 |
| Oct 26 | 4 | 1 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
6 more in this ranking with a free account
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
7 more in this ranking with a free account
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2913-2026 · Started Apr 20, 2026 · Posted by FDA Aug 7, 2026
Reason given: Due to complaints received for the Image Management System regarding image/metadata discrepancy with the Viewer window
Cause as FDA categorized it: Software design · Device type: Whole Slide Imaging System (PSY)
Z-2644-2024 · Started Jun 27, 2024 · Posted by FDA Aug 16, 2024
Reason given: Their is a potential for high background and off-target staining when using the monoclonal primary antibody which can result in false positive results.
Cause as FDA categorized it: Unknown/Undetermined by firm · Device type: Immunohistochemistry Reagents And Kits (NJT)
Z-0907-2023 · Started Nov 18, 2022 · Posted by FDA Jan 6, 2023
Reason given: Internal comparison studies revealed unacceptable, light staining. Light staining affects the borderline of positive versus negative test results. It can cause a reduction in both staining intensity and the percent positivity, which could potentially lead to a false-negative PD-L1 result.
Cause as FDA categorized it: Process design · Device type: Immunohistochemistry Assay, Antibody, Programmed Death-Ligand 1 (PLS)
53 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.